Lonza Group AG: management transactions · Switzerland · SIX SER

About Lonza Group AG

Lonza Group AG is one of the world’s leading contract development and manufacturing organizations (CDMOs) serving the healthcare industry. Listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland, the company offers investors exposure to high-value pharmaceutical outsourcing, with a business model centered on innovation, regulatory quality and industrial complexity. Founded in 1897 in the Swiss Alps, Lonza has evolved from a historic industrial group into a global specialist in development and manufacturing services for biopharma and biotechnology customers. Its headquarters are in Basel, at the heart of one of Switzerland’s most important life-sciences clusters. Lonza’s core economic model is built around end-to-end services, from early development through to drug substance and drug product manufacturing. The group operates across a broad set of technology platforms, including mammalian biologics, small molecules, highly potent active pharmaceutical ingredients (HPAPIs), bioconjugates, mRNA, microbial processes, and cell and gene therapies. This technological breadth is strategically important because it allows Lonza to address complex, high-barrier projects that typically involve long development cycles, stringent quality requirements and deep customer integration. From a competitive standpoint, Lonza is positioned among the reference names in the global CDMO market, alongside other major international outsourcing specialists. Its differentiation lies in its technical depth, its global industrial footprint and its reputation as a long-term partner for innovative drug developers. The company emphasizes an integrated offering spanning R&D support through commercial-scale manufacturing, which strengthens customer retention and supports medium-term revenue visibility. Geographically, Lonza operates a worldwide network of development and manufacturing sites across Europe, North America and Asia. This international footprint enables the group to serve multinational clients while preserving a strong historical base in Switzerland. In late 2024, Lonza announced a new strategic organization, reinforcing its focus on the core CDMO business and moving toward a simplified operating structure that became effective in 2025. Recent highlights include management’s characterization of 2024 as a defining transformation year, marked by the launch of the “One Lonza Group” strategy, board-level governance enhancements and a sharper focus on long-term value creation. The company also discussed the evolution of its integrated platforms, notably around biologics, advanced synthesis and specialized modalities. For investors, Lonza combines a high-quality healthcare franchise, exposure to structurally growing pharmaceutical outsourcing demand, and operational leverage tied to the expansion of complex biologic and specialty manufacturing services.